Biocad
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS21
PHASE 3 / 2-313
RECRUITING9
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO8%
Delay Index: of 12 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Biocad on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| OCTAVA NCT05732805 |
P3 | Active, not recruiting | Melanoma; Melanoma (Skin) | 270 | 2024-06-20 |
| Levilimab NCT05800327 |
P3 | Active, not recruiting | Rheumatoid Arthritis | 261 | 2024-09 |
| LIBERIUS NCT05726630 |
P3 | Active, not recruiting | Systemic Scleroderma | 152 | 2024-10-01 (+2 mo) |
| anti-TRBV9 monoclonal antibody infusions NCT06333210 |
P3 | Active, not recruiting | Axial Spondyloarthritis | 421 | 2024-12 |
| AQUARELLE NCT05730699 |
P3 | Active, not recruiting | Neuromyelitis Optica Spectrum Disorders | 105 | 2025-01 |
| PREFER NCT05802225 |
P3 | Active, not recruiting | Breast Cancer | 398 | 2025-06-06 (+16 mo) |
| BLUEBELL NCT05747261 |
P1/2 | Recruiting | Spinal Muscular Atrophy (SMA) | 40 | 2025-09 |
| ANB-002, dose 1 NCT06120582 |
P1/2 | Recruiting | Hemophilia B | 28 | 2025-11 |
| AREAL NCT07108309 |
P2 | Recruiting | Triple Negative Breast Cancer | 124 | 2025-12 |
| EDELWEISS NCT06185335 |
P1/2 | Active, not recruiting | Hemophilia A | 50 | 2025-12 |
| ELEFTA NCT05445076 |
P2 | Active, not recruiting | Axial Spondyloarthritis | 250 | 2025-12 |
| UNIVERSE NCT06640530 |
P3 | Active, not recruiting | Advanced Melanoma; Melanoma (Skin) | 392 | 2025-12 |
| FLAMMINGO NCT06668792 |
P2 | Recruiting | Relapsed/Refractory Multiple Myeloma | 100 | 2026-02 |
| BCD-131 (pegdarbepoetin beta) NCT07119372 |
P3 | Active, not recruiting | Anemia; Chronic Kidney Disease | 228 | 2026-05-12 |
| PLANETA-KIDS NCT06640517 |
P3 | Active, not recruiting | Plaque Psoriasis | 140 | 2026-06 |
| NEO-MIMAJOR NCT05751928 |
P3 | Active, not recruiting | Melanoma Stage III; Melanoma (Skin) | 411 | 2027-01 |
| ULTRAMARINE NCT07080034 |
P2 | Recruiting | Ulcerative Colitis (UC) | 198 | 2027-01 |
| MAGNOLIA NCT06700096 |
P3 | Recruiting | Hemophilia B | 24 | 2027-04 |
| COMANDOR NCT07078994 |
P2 | Recruiting | Crohn's Disease (CD) | 204 | 2027-05 |
| AMMADINA NCT07742215 |
P3 | Recruiting | Myeloma Multiple | 390 | 2028-07 |
| MUSCAT NCT07321093 |
P3 | Recruiting | Relapsing-remitting Multiple Sclerosis (RRMS) | 292 | 2028-12 |